Akeso highlights collaboration between its partner Summit Therapeutics and Pfizer to explore Ivonescimab in combination...

MEDSIR & Debiopharm announce the first patient dosed in the WIN-B trial exploring the combination...

Radiance Biopharma enters exclusive license for ROR-1 targeted Antibody Drug Conjugate (ADC)

Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities

Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer

PADCEV ® (enfortumab vedotin) in combination with pembrolizumab approved by Health Canada to treat advanced...

Merck & Co. bags one Kelun ADC for $37.5M, boots out another asset as pipeline...

Denmark’s Adcendo signs $1B biobuck deal for Multitude’s anti-TF ADC

FDA greenlights BioNTech/Medilink’s cancer trial at lower dose after deaths